Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: Does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

BJU International

Volumn 109, Issue 4, 2012, Pages 549-556

  Geavlete, Bogdan ^a   Multescu, Razvan ^a   Georgescu, Dragos ^a   Jecu, Marian ^a   Stanescu, Florin ^a   Geavlete, Petrisor ^a  

^a Saint John Emergency Clinical Hospital   (Romania)

Author keywords

diagnostic accuracy; hexaminolevulinate blue light cystoscopy; non muscle invasive bladder cancer; recurrence rates; treatment changes

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ARTICLE; BLADDER CANCER; BLUE LIGHT CYSTOSCOPY; CANCER DIAGNOSIS; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PHOTODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TRANSURETHRAL RESECTION; UROGENITAL ENDOSCOPY; WHITE LIGHT CYSTOSCOPY;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CONTRAST MEDIA; CYSTOSCOPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENTAL FINDINGS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84857034477     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10374.x     Document Type: Article

References (31)

1. Grasso M,. Bladder cancer: a major public health issue. Eur Urol Suppl 2008; 7: 510-5
2. Sylvester RJ, van der Meijden AP, Lamm DL,. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
3. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W,. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168: 67-71 (Pubitemid 34640786)
4. Koenig F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF,. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999; 83: 129-35 (Pubitemid 29151420)
5. Marti A, Jichlinski P, Lange N, et al,. Comparison of aminolevulinic acid and hexylesteraminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003; 170: 428-32 (Pubitemid 36870217)
6. Witjes JA, Redorta JP, Jacqmin D, et al,. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010; 57: 607-14
7. Zaak D, Kriegmair M, Stepp H, et al,. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001; 57: 690-4
8. Denzinger S, Burger M, Walter B, et al,. Clinically relevant reduction of risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69: 675-9 (Pubitemid 46574917)
9. Babjuk M, Oosterlinck W, Sylvester R, et al,. Guidelines on TaT1 (non-muscle invasive) Bladder Cancer. European Association of Urology Guidelines, 2010 edn. Available at:. Accessed April 2011
10. Jocham D, Stepp H, Waidelich R,. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 2008; 53: 1138-48
11. Fradet Y, Grossman HB, Gomella L, et al,. PC B302/01 Study Group. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 68-73 (Pubitemid 46908730)
12. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M,. Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 135-8 (Pubitemid 37549108)
13. Jocham D, Witjes F, Wagner S, et al,. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 862-6 (Pubitemid 41140613)
14. Grossman HB, Gomella L, Fradet Y, et al,. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178: 62-7 (Pubitemid 46908731)
15. Kausch I, Sommerauer M, Montorsi F, et al,. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010; 57: 595-606
16. Jichlinski P, Guillou L, Karlsen SJ, et al,. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer -a multicenter study. J Urol 2003; 170: 226-9 (Pubitemid 36734467)
17. Abascal Junquera JM, Hevia Suárez M, Abascal García JM, Estébanez C, Astudillo A, Abascal R,. [Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix]. Arch Esp Urol 2008; 61: 475-82
18. Thomas K, O'Brien T,. Blue-sky thinking about blue-light cystoscopy. BJU Int 2009; 104: 887-90
19. Lee CS, Yoon CY, Witjes JA,. The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int 2008; 102: 1228-33
20. Brausi M, Collette L, Kurth K, et al,. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523-31
21. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H,. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001; 165: 1121-3 (Pubitemid 32210216)
22. Stenzl A, Burger M, Fradet Y, et al,. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184: 1907-13
23. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al,. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-77
24. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J,. 5-aminolaevulinic acid -induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96: 798-802 (Pubitemid 41391384)
25. Daniltchenko DI, Riedl CR, Sachs MD, et al,. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005; 174: 2129-33 (Pubitemid 41611752)
26. Landry JL, Gelet A, Bouvier R, Dubernard JM, Martin X, Colombel M,. Detection of bladder dysplasia using 5-aminolaevulinic acid-induced porphyrin fluorescence. BJU Int 2003; 91: 623-6 (Pubitemid 36583731)
27. Burger M, Stief CG, Zaak D, et al,. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology 2009; 74: 1282-6
28. Schumacher MC, Holmäng S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP,. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 2010; 57: 293-9
29. Hungerhuber E, Stepp H, Kriegmair M, et al,. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007; 69: 260-4 (Pubitemid 46274934)
30. Denzinger S, Wieland WF, Otto W, Filbeck T, Knuechel R, Burger M,. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 2008; 101: 566-9 (Pubitemid 351199276)
31. Stanislaus P, Zaak D, Stadler T, et al,. Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate. World J Urol 2010; 28: 407-11